Rallybio Corporation
RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Tā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.79
Price+0.93%
$0.01
1Y
Price
Market Cap
$33.161m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+7571.2%
EBITDA Margin+7554.7%
Net Profit Margin-3089.6%
Free Cash Flow MarginRevenue
$674k
+6.0%
1y CAGR+2.0%
3y CAGR+1.5%
5y CAGREarnings
-$14.170m
+75.5%
1y CAGR+28.7%
3y CAGR+11.1%
5y CAGREPS
-$0.32
+75.9%
1y CAGR+38.5%
3y CAGR+18.1%
5y CAGRBook Value
$63.034m
$67.661m
Assets$4.627m
Liabilities$198k
DebtDebt to Assets
0.3%
-
Debt to EBITDAFree Cash Flow
-$34.996m
+29.0%
1y CAGR+14.0%
3y CAGR+4.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company